Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension

References

• Rosenzweig EB. Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006;11(4):609–619.
   PubMedGoogle Scholar
• Sardana M, Moll M, Farber HW. Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opin Investig Drugs. 2015;24(12):1571–1596.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329.
   PubMed Web of Science ®Google Scholar
• Collum SD, Amione-Guerra J, Cruz-Solbes AS, et al. Pulmonary hypertension associated with idiopathic pulmonary fibrosis: current and future perspectives. Can Respir J. 2017 20171430350.
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–649.
   PubMed Web of Science ®Google Scholar
• Tanabe N, Taniguchi H, Tsujino I, et al. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology. 2015;20(5):805–812.
   PubMed Web of Science ®Google Scholar
• Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013;143(6):1699–1708.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900.
   PubMed Web of Science ®Google Scholar
• Sajkov D, Mupunga B, Bowden JJ, et al. Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia, 2013.
   Google Scholar
• Bozyk PD, Moore BB. Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(3):445–452.
   PubMed Web of Science ®Google Scholar
• Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009;156(3):534–544.
   PubMed Web of Science ®Google Scholar
• Glickman JF, Schmid A, Ferrand S. Scintillation proximity assays in high-throughput screening. Assay Drug Dev Technol. 2008;6(3):433–455.
   PubMed Web of Science ®Google Scholar
• Nio Y, Tanaka M, Hirozane Y, et al. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy. FASEB J. 2017;31(12): 5307–5320.
   PubMed Web of Science ®Google Scholar
• Shen X, Hu PP, Liberati NT, et al. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol Biol Cell. 1998;9(12):3309–3319.
   PubMed Web of Science ®Google Scholar
• Gong K, Xing D, Li P, et al. cGMP inhibits TGF-beta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery smooth muscle cells. Mol Endocrinol. 2011;25(10):1794–1803.
   PubMedGoogle Scholar
• Schinner E, Wetzl V, Schramm A, et al. Inhibition of the TGFbeta signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis. FEBS Open Bio. 2017;7(4):550–561.
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Jahn L, Takahashi T, et al. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem. 1992;267(15):10551–10560.
   PubMed Web of Science ®Google Scholar
• Adachi S, Ito H, Ohta Y, et al. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol. 1995;268(1 Pt 2):H162–169.
   PubMedGoogle Scholar
• Morgado M, Cairrao E, Santos-Silva AJ, et al. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci. 2012;69(2):247–266.
   PubMed Web of Science ®Google Scholar
• Kuhr FK, Smith KA, Song MY, et al. New mechanisms of pulmonary arterial hypertension: role of Ca(2)(+) signaling. Am J Physiol Heart Circ Physiol. 2012;302(8):H1546–1562.
   PubMed Web of Science ®Google Scholar
• Golovina VA, Platoshyn O, Bailey CL, et al. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001;280(2):H746–755.
   PubMed Web of Science ®Google Scholar
• Molteni A, Ward WF, Ts’ao CH, et al. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med. 1985;180(1):112–120.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Yonemitsu Y, Kataoka C, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2002;283(5):H2021–2028.
   PubMed Web of Science ®Google Scholar
• Mercer PF, Johns RH, Scotton CJ, et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5):414–425.
   PubMed Web of Science ®Google Scholar
• Moore BB, Peters-Golden M, Christensen PJ, et al. Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L342–349.
   PubMed Web of Science ®Google Scholar
• Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877–1890.
   PubMed Web of Science ®Google Scholar
• Milara J, Peiro T, Serrano A, et al. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD. Pulm Pharmacol Ther. 2014;28(2):138–148.
   PubMed Web of Science ®Google Scholar
• Greene KE, King TE Jr., Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439–446.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961.
   PubMed Web of Science ®Google Scholar